Description: TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Health Care Unit, Anti-infection Business Unit, Domestic Cardiovascular and Gastrointestinal Drugs Business Unit, China Medicine Business Unit, and Other segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, Veiasu, and Pemazyre names for anti-cancer and supplementary treatments. The company also provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. The company was founded in 1960 and is headquartered in Taipei, Taiwan.
Home Page: eng.tty.com.tw
No.3-1, Park Street
Taipei,
11503
Taiwan
Phone:
886 2 2652 5999
Officers
| Name | Title |
|---|---|
| Mr. Kuo-Chiang Chang | CFO, Corp. Governance Officer & Sr. Assistant VP of Financial Division |
| Ms. Shu-Wen Wang | Accounting Officer |
| Ms. Shu-Fen Huang | Chief Legal & Compliance Officer |
| Wei-Ying Yin | Director of Public Affairs Department |
| Mr. Jen-Yang Chang | Chief Human Resource Officer |
| Ms. Si-Yuan Yang | Sr. VP |
| Mr. Allen Chu | Head of Intensive Care Bus. Unit |
| Ms. Ching-Lan Hou | Gen. Mang. |
| Yung-Min Chiang | Internal Audit Officer |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 16.7785 |
|---|---|
| Trailing PE: | 16.5336 |
| Price-to-Book MRQ: | 3.7773 |
| Price-to-Sales TTM: | 4.1 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |